PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease

被引:76
作者
Huang, Kun [1 ,2 ]
Du, Meng [1 ,2 ]
Tan, Xin [1 ,2 ]
Yang, Ling [1 ,3 ]
Li, Xiangrao [1 ,2 ]
Jiang, Yuhan [1 ,2 ]
Wang, Cheng [1 ,2 ]
Zhang, Fengxiao [1 ,2 ]
Zhu, Feng [1 ,2 ]
Cheng, Min [1 ,2 ]
Yang, Qinglin [4 ]
Yu, Liqing [5 ]
Wang, Lin [6 ]
Huang, Dan [1 ,2 ]
Huang, Kai [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Clin Ctr Human Gene Res, Wuhan, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Cardiol, Wuhan, Peoples R China
[3] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Div Gastroenterol,Dept Internal Med, Wuhan, Peoples R China
[4] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA
[5] Univ Maryland, Dept Anim & Avian Sci, College Pk, MD 20742 USA
[6] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Clin Lab, Wuhan, Peoples R China
基金
中国国家自然科学基金;
关键词
Non-alcoholic fatty liver disease; Poly(ADP-ribose) polymerase 1; PPAR alpha; Transcriptional regulation; High fat diet; ACTIVATED RECEPTOR-ALPHA; HEPATIC STEATOSIS; LIPID-METABOLISM; INFLAMMATION; FENOFIBRATE; FIBROSIS; PARP-1; MOUSE; STEATOHEPATITIS; POLYMERASE-1;
D O I
10.1016/j.jhep.2016.11.020
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: PARP1 is a key mediator of cellular stress responses and critical in multiple physiological and pathophysiological processes of cells. However, whether it is involved in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) remains elusive. Methods: We analysed PARP1 activity in the liver of mice on a high fat diet (HFD), and samples from NAFLD patients. Gain- or loss-of-function approaches were used to investigate the roles and mechanisms of hepatic PARP1 in the pathogenesis of NAFLD. Results: PARP1 is activated in fatty liver of HFD-fed mice. Pharmacological or genetic manipulations of PARP1 are sufficient to alter the HFD-induced hepatic steatosis and inflammation. Mechanistically we identified peroxisome proliferator-activated receptor alpha (PPAR alpha) as a substrate of PARP1-mediated poly (ADP-ribosyl) ation. This poly(ADP-ribosyl) ation of PPAR alpha inhibits its recruitment to target gene promoters and its interaction with SIRT1, a key regulator of PPAR alpha signaling, resulting in suppression of fatty acid oxidation upregulation induced by fatty acids. Moreover, we show that PARP1 is a transcriptional repressor of PPAR alpha gene in human hepatocytes, and its activation suppresses the ligand (fenofibrate)-induced PPARa transactivation and target gene expression. Importantly we demonstrate that liver biopsies of NAFLD patients display robust increases in PARP activity and PPAR alpha poly(ADP-ribosyl) ation levels. Conclusions: Our data indicate that PARP1 is activated in fatty liver, which prevents maximal activation of fatty acid oxidation by suppressing PPAR alpha signaling. Pharmacological inhibition of PARP1 may alleviate PPARa suppression and therefore have therapeutic potential for NAFLD. Lay summary: PARP1 is activated in the non-alcoholic fatty liver of mice and patients. Inhibition of PARP1 activation alleviates lipid accumulation and inflammation in fatty liver of mice. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:962 / 977
页数:16
相关论文
共 43 条
[1]   PPARα Expression Protects Male Mice from High Fat-Induced Nonalcoholic Fatty Liver [J].
Abdelmegeed, Mohamed A. ;
Yoo, Seong-Ho ;
Henderson, Lauren E. ;
Gonzalez, Frank J. ;
Woodcroft, Kimberley J. ;
Song, Byoung-Joon .
JOURNAL OF NUTRITION, 2011, 141 (04) :603-610
[2]   The genetics of NAFLD [J].
Anstee, Quentin M. ;
Day, Christopher P. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (11) :645-655
[3]   Signaling Mechanism of Poly(ADP-Ribose) Polymerase-1 (PARP-1) in Inflammatory Diseases [J].
Ba, Xueqing ;
Garg, Nisha Jain .
AMERICAN JOURNAL OF PATHOLOGY, 2011, 178 (03) :946-955
[4]   PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation [J].
Bai, Peter ;
Canto, Caries ;
Oudart, Hugues ;
Brunyanszki, Attila ;
Cen, Yana ;
Thomas, Charles ;
Yamamoto, Hiroyasu ;
Huber, Aline ;
Kiss, Borbala ;
Houtkooper, Riekelt H. ;
Schoonjans, Kristina ;
Schreiber, Valerie ;
Sauve, Anthony A. ;
Menissier-de Murcia, Josiane ;
Auwerx, Johan .
CELL METABOLISM, 2011, 13 (04) :461-468
[5]   Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus [J].
Bajaj, M. ;
Suraamornkul, S. ;
Hardies, L. J. ;
Glass, L. ;
Musi, N. ;
DeFronzo, R. A. .
DIABETOLOGIA, 2007, 50 (08) :1723-1731
[6]   Implication of Gut Microbiota in Nonalcoholic Fatty Liver Disease [J].
Boursier, Jerome ;
Diehl, Anna Mae .
PLOS PATHOGENS, 2015, 11 (01) :1-6
[7]   Metabolic endotoxemia with obesity: Is it real and is it relevant? [J].
Boutagy, Nabil E. ;
McMillan, Ryan P. ;
Frisard, Madlyn I. ;
Hulver, Matthew W. .
BIOCHIMIE, 2016, 124 :11-20
[8]   Molecular mediators of hepatic steatosis and liver injury [J].
Browning, JD ;
Horton, JD .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (02) :147-152
[9]   Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice [J].
Carmona, MC ;
Louche, K ;
Nibbelink, M ;
Prunet, B ;
Bross, A ;
Desbazeille, M ;
Dacquet, C ;
Renard, P ;
Casteilla, L ;
Pénicaud, L .
INTERNATIONAL JOURNAL OF OBESITY, 2005, 29 (07) :864-871
[10]   PARP1 deficiency exacerbates diet-induced obesity in mice [J].
Devalaraja-Narashimha, Kishor ;
Padanilam, Babu J. .
JOURNAL OF ENDOCRINOLOGY, 2010, 205 (03) :242-251